{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:22:36Z","timestamp":1768537356613,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study compared the radiomic features and quantitative biomarkers of <jats:sup>18<\/jats:sup>F-PSMA-1007 [prostate-specific membrane antigen (PSMA)] and <jats:sup>18<\/jats:sup>F-fluorocholine (FCH) PET\/computed tomography (CT) in prostate cancer patients with biochemical recurrence (BCR) enrolled in the phase 3, prospective, multicenter BIO-CT-001 trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 106 patients with BCR, who had undergone primary definitive treatment for prostate cancer, were recruited to this prospective study. All patients underwent one PSMA and one FCH PET\/CT examination in randomized order within 10 days. They were followed up for a minimum of 6 months. Pathology, prostate-specific antigen (PSA), PSA doubling time, PSA velocity, and previous or ongoing treatment were analyzed. Using LifeX software, standardized uptake value (SUV) maximum, SUV<jats:sub>mean<\/jats:sub>, PSMA and choline total volume (PSMA-TV\/FCH-TV), and total lesion PSMA and choline (TL-PSMA\/TL-FCH) of all identified metastatic lesions in both tracers were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 286 lesions identified, the majority 140 (49%) were lymph node metastases, 118 (41.2%) were bone metastases and 28 lesions (9.8%) were locoregional recurrences of prostate cancer. The median SUV<jats:sub>max<\/jats:sub> value was significantly higher for <jats:sup>18<\/jats:sup>F-PSMA compared with FCH for all 286 lesions (8.26 vs. 4.99, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). There were statistically significant differences in median SUV<jats:sub>mean<\/jats:sub>, TL-PSMA\/FCH, and PSMA\/FCH-TV between the two radiotracers (4.29 vs. 2.92, 1.97 vs. 1.53, and 7.31 vs. 4.37, respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). The correlation between SUV<jats:sub>mean<\/jats:sub>\/SUV<jats:sub>max<\/jats:sub> and PSA level was moderate, both for <jats:sup>18<\/jats:sup>F-PSMA (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.44, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001; <jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.44, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001) and FCH (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.35, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001; <jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.41, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). TL-PSMA\/FCH demonstrated statistically significant positive correlations with both PSA level and PSA velocity for both <jats:sup>18<\/jats:sup>F-PSMA (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.56, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001; <jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.57, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001) and FCH (<jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.49, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001; <jats:italic toggle=\"yes\">r<\/jats:italic>\u2005=\u20050.51, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). While patients who received hormone therapy showed higher median SUV<jats:sub>max<\/jats:sub> values for both radiotracers compared with those who did not, the difference was statistically significant only for <jats:sup>18<\/jats:sup>F-PSMA (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our analysis using both radiomic features and quantitative biomarkers demonstrated the improved performance of <jats:sup>18<\/jats:sup>F-PSMA-1007 compared with FCH in identifying metastatic lesions in prostate cancer patients with BCR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001867","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:35:58Z","timestamp":1717479358000},"page":"796-803","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Towards improved diagnosis: radiomics and quantitative biomarkers in 18F-PSMA-1007 and 18F-fluorocholine PET\/CT for prostate cancer recurrence"],"prefix":"10.1097","volume":"45","author":[{"given":"Emmanouil","family":"Panagiotidis","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotiria","family":"Andreou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Paschali","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyra","family":"Angeioplasti","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaggelia","family":"Vlontzou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Evaggelismos\u2019 General Hospital, Athens\u2002and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Kalathas","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Pipintakou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Fothiadaki","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Evaggelismos\u2019 General Hospital, Athens\u2002and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Makridou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chatzimarkou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Papanastasiou","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Physics and Digitial Innovation, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Datseris","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Evaggelismos\u2019 General Hospital, Athens\u2002and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Chatzipavlidou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine \u2013 PET\/CT, \u2018Theageneio\u2019 Cancer Center, Thessaloniki,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"R2-20250807","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.","volume":"27","author":"Shore","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R3-20250807","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7150\/thno.4008","article-title":"Choline PET and PET\/CT in primary diagnosis and staging of prostate cancer.","volume":"2","author":"Schwarzenb\u00f6ck","year":"2012","journal-title":"Theranostics"},{"key":"R4-20250807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-021-01537-3","article-title":"PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer.","volume":"38","author":"Parsi","year":"2021","journal-title":"Med Oncol"},{"key":"R5-20250807","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study.","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"key":"R6-20250807","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00259-018-3952-0","article-title":"Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20250807","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer.","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20250807","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study.","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl Med Commun"},{"key":"R9-20250807","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MNM.0000000000001786","article-title":"Review of artificial intelligence clinical applications in Nuclear Medicine.","volume":"45","author":"Panagiotidis","year":"2024","journal-title":"Nucl Med Commun"},{"key":"R10-20250807","first-page":"57","article-title":"Artificial intelligence in nuclear medicine physics and imaging.","volume":"26","author":"Papachristou","year":"2023","journal-title":"Hell J Nucl Med"},{"key":"R11-20250807","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00259-022-06001-6","article-title":"Joint EANM\/SNMMI guideline on radiomics in nuclear medicine.","volume":"50","author":"Hatt","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20250807","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.","volume":"64","author":"Olivier","year":"2022","journal-title":"J Nucl Med"},{"key":"R13-20250807","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/2191-219X-3-63","article-title":"Optimized dose regimen for whole-body FDG-PET imaging.","volume":"3","author":"de Groot","year":"2013","journal-title":"EJNMMI Res"},{"key":"R14-20250807","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large b-cell lymphoma are predictive of outcome.","volume":"61","author":"Cottereau","year":"2020","journal-title":"J Nucl Med"},{"key":"R15-20250807","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"Image biomarker standardisation initiative.","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"R16-20250807","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity.","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"R17-20250807","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1038\/s41598-020-69577-9","article-title":"Comparison of different automatic methods for the delineation of the total metabolic tumor volume in I-II stage Hodgkin lymphoma.","volume":"10","author":"Mart\u00edn-Saladich","year":"2020","journal-title":"Sci Rep"},{"key":"R18-20250807","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","article-title":"PSA velocity and doubling time in diagnosis and prognosis of prostate cancer.","volume":"5","author":"Vickers","year":"2012","journal-title":"Br J Med Surg Urol"},{"key":"R19-20250807","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy.","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"R20-20250807","first-page":"127","article-title":"Radiolabelled choline versus PSMA PET\/CT in prostate cancer restaging: a meta-analysis.","volume":"9","author":"Treglia","year":"2019","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"R21-20250807","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/diagnostics12123176","article-title":"Recurrent prostate cancer diagnostics with 18F-PSMA-1007 PET\/CT: a systematic review of the current state.","volume":"12","author":"Saule","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R22-20250807","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/pros.21377","article-title":"The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.","volume":"71","author":"Keizman","year":"2011","journal-title":"Prostate"},{"key":"R23-20250807","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13550-021-00783-w","article-title":"Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer.","volume":"11","author":"Ahmadi Bidakhvidi","year":"2021","journal-title":"EJNMMI Res"},{"key":"R24-20250807","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","article-title":"Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer.","volume":"47","author":"Ettala","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20250807","doi-asserted-by":"crossref","first-page":"1758835920987654","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R26-20250807","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/RLU.0000000000002354","article-title":"Rib fractures mimicking bone metastases in 18F-PSMA-1007 PET\/CT for prostate cancer.","volume":"44","author":"Panagiotidis","year":"2019","journal-title":"Clin Nucl Med"},{"key":"R27-20250807","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:00:32Z","timestamp":1754596832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001867","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}